Peptides for senior dogs

Reading the research

Each peptide needs to be considered separately. The species studied and the outcome measured determine how much a finding can tell us about a dog's care. Two examples illustrate the questions a veterinarian needs to work through.

BPC-157: rat tendon cells

Chang and colleagues studied cells taken from rat Achilles tendons in a laboratory. Their work examined growth-hormone receptor expression. Applying this finding to an older dog's mobility would require evidence in the relevant patients. Read the 2014 study.

MOTS-c: physical performance in mice

A 2021 study reported improved physical performance in mice given MOTS-c. For a canine case, questions remain about safety and whether comparable changes would occur in dogs with an existing disease. Reynolds and colleagues.

These studies do not establish an effective treatment or a safe dose for senior dogs. A proposed protocol needs an individual veterinary assessment of the evidence and the patient.

Reviewing a mobility problem

Changes attributed to aging can involve chronic pain. The AAHA senior-care guidelines describe assessment and ongoing monitoring, with treatment adapted to the animal. They also recommend home videos to help a veterinarian understand changes in movement.

For a Doctor Canine review, include the diagnosis and recent records along with current medications and any previous adverse reactions. Describe what has changed during ordinary activities and what your treating veterinarian has already tried. The review needs to account for the care your dog is receiving now.

Questions about the product

Ask who would prescribe and dispense a proposed medication, and what information is available about its preparation. The FDA explains that compounded animal drugs are not FDA-approved. Their safety and effectiveness have not received the same premarket review as an approved finished drug. A veterinarian must assess whether a proposed option is appropriate and legally available for the individual patient.